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ABSTRACT 
The present study was undertaken to evaluate the effects of Harungana madagascariensis on 
electrocardiographycal, biochemical and histopathological changes in isoproterenol (ISO)-
induced myocardial infarction. Male Wistar albino rats were randomly divided and treated 
with aqueous extract of Harungana madagascariensis stem bark (AEHM, 200 and 400 
mg/kg per os), or normal saline or vitamin E for 7 days with concomitant administration of 
ISO (85 mg/kg, subcutaneously) on8th and 9th days, at 24 h interval.The ISO injections to 
the rats caused cardiac dysfunction evidenced by a marked (P<0.01) elevation in ST-segment, 
a reduction in R wave amplitude (P < 0.01), decrease in endogenous antioxidant reduced 
glutathione (GSH), increase in malondialdehyde (MDA), a lipid peroxidation marker, 
increase of cardiac marker enzymes lactate dehydrogenase (LDH), aspartate amino 
transferase(AST) and alanine amino transferase (ALT). All these changes in cardiac function 
as well as GSH, MDA and the enzymes (LDH, AST and ALT) were ameliorated when the 
rats were pretreated with AEHM. Additionally, the protective effects were strengthened by 
improved histopathological changes, which specifies the protection of cardiomyocytes from 
the deleterious effects of ISO. This study demonstrates the cardioprotective effect of 
Harungana madagascariensison isoproterenol-induced myocardial infarction in rats. The 
mechanism might be associated with the enhancement of antioxidant defense, reduction of 
lipid peroxydation and is confirmed by amending electrocardiographic pattern, improvement 
of cardiac markers and less histopathological damages following ISO-induced myocardial 
infarction. It could provide experimental evidence to support the use of Harungana 
madagascariensisused in traditional medicine to treat cardiovascular disorders. 
Keywords: Antioxydants, electrocardiography, Harungana madagascarienis, isoproterenol, 
myocardial infarction. 
INTRODUCTION 
According to the recent world health organization survey,an estimated 17.7 million people 
died from to cardiovascular disease (CVDs) in 2015, representing 31% of all global deaths. 
Of these deaths, an estimated 80% were due to myocardial infarctions (MI) and strokes
1
. 
According to the same survey, over three quarters of CVDs deaths occurred in low- and 
middle-income countries. MI is followedby several biochemical alterations, such as lipid 
peroxidation, free radical damage,hyperglycemia, hyperlipidemia, elevation in cardiac 
markers and pro-inflammatorycytokines leading to qualitative and quantitative alterations of 
myocardium
2
.Catecholamines at low concentrations are beneficial in regulating heart 
functions by exerting a positive inotropic action on the myocardium
3
, whereas high 
concentrations of catecholamines or chronic exposure to catecholamines over a prolonged 
period produces deleterious effects on the cardiovascular system
4
.Isoproterenol (ISO) is a 
synthetic catecholamine, a nonselective β-adrenoreceptor agonist, which causes severe stress 
in the myocardium and produces infarct like lesions, when injected in rats
5
.The ISO model is 
a well standardized and most reliable model for assessing the cardioprotective activity of 
several drugs, since it pathophysiological and morphological changes following ISO 
administration are comparable to those taking place in human MI
6
. Now a days, a number of 
pharmacological interventions such as beta-blockers, ACE inhibitors, antiplatelet agents, 
thrombolytics, calcium antagonist, nitrates, antioxidants have been shown to counteract the ill 
effect of myocardial ischemic injury, and to reduce morbidity and mortality in patients with 
 ischemic heart disease
7, 8
. However, their chronic usage is often associated with adverse 
effects
9
. Therefore, the development of new and safer drugs for the treatment and prevention 
of ischemic heart disease is still a major concern. There is increasing trend towards the 
application of herbal medicines to treat the cardiovascular diseases
10, 11
. Harungana 
madagascariensis is one of the most popular trees in the African traditional medicine system. 
It is used as an abortifacient and antiseptic, in the treatment of cardiovascular disorders, 
anemia, asthma, tuberculosis, fever, angina, , diarrhea, dysentery, syphilis, gonorrhea, 
malaria, parasitic skin diseases, and wounds, as a natural source of dermatological agents and 
cosmetics
12-16
,asthma, liver diseases, diabetes, pancreatic and biliary problems
17,18
. Studies on 
the barks or leaves of this plant revealed antihelminthiase properties
19
, anti-plasmodial
20
, 
antidiabetic
21
, antimicrobial activities
22
, analgesic and anti-inflammatory activities
23
. A 
prenylated 1, 4-anthraquinone isolated from the hexane extract of the stem-bark of H. 
madagascariensis possess alpha-glucosidase inhibition and antioxidant activities
24
.In this 
context, an attempt has been made to investigate the effect of anaqueous extract ofH. 
madagascariensis on maintaining the myocardial integrity in animals employing 
electrocardiographical, biochemical and histopathological parameters in ISO-
inducedmyocardial infarction. 
MATERIALS AND METHODS 
Plant material collection and extraction 
Fresh H. madagascariensis stem barks were collected at Essezok, Mbalmayo (Center Region, 
Cameroon) in June 2016. The identification of the plant was done at the Cameroon National 
Herbarium where voucher sample were deposited under the registration number N° 4224 
HNC. Bark pieces were dried under room temperature and powdered with the help of 
electrical grinder. 500 g of powder was introduced into 3.5 L of distilled water and boiled for 
20 minutes. The resulting decoction was filtered through Whatman paper N°3 and further 
lyophilized. A crude brown extract powder (HM extract, 31.73g) was obtained, giving a yield 
of 6.35%. 
Experimental animals 
Male albino Wistar rats (150-200g) were obtained from the Animal House of the Faculty of 
Science at the University of Yaoundé I (Cameroon). They were kept at standard laboratory 
conditions under natural light and dark cycles, at constant room temperature (20±5°C) and 
were allowed to have standard food and tap water freely. This study wasapproved by the 
Cameroonian National Ethical Committee (Ref n◦FW-IRB00001954). 
Drugs and chemicals 
Isoroterenol hydrochloride was purchased from Sigma Aldrich, USA. Lactate 
deshydrogenase (LDH) kit for enzyme estimation was purchased from Hospitex Diagnostics. 
Aspartate amino transferase (AST) and alanine amino transferase (ALT) kits were from 
Fortress Diagnostics Biosystems. All chemicals used in the present study were of analytical 
grade. 
Induction of experimental myocardial infarction 
Isoproterenol was freshly dissolved in 0.9% saline and injected (85 mg/kg) subcutaneously to 
the rats for two successive days (on days 8th and 9th respectively) at an interval of 24h. 
Animals were sacrificed 48h after the first injection of isoproterenol. 
Experimental design 
The animals were randomized into 7 groups consisting of 7 rats each. HM extract was 
dissolved in distilled water. Vitamin E was used as standard drug. Rats in group 1 (normal 
control) received distilled water (10 mL/kg) orally, for 9 days. Rats in group 2 (ISO control) 
received distilled water for 9 daysand were injected isoproterenol (85 mg/kg, SC) on the 8th 
and 9th days at an interval of 24 hour. Animals of groups 3 to 5 were pretreated with the 
 aqueous extract of HM (200 and 400 mg/kg/day) or vitamin E (100 mg/kg/day) orally for 9 
days and on the 8th and 9th days they received isoproterenol SC at an interval of 24 hour. 
Rats in groups 6 and 7 were treated with the aqueous extract of HM (400 mg/kg/day) and 
vitamin E (100 mg/kg/day) orally for 9 days and on the 8th and 9th days they were injected 
saline (0.1mL/100g SC) at an interval of 24 hour. Changes in body weight in all groups were 
noted every 2 days during the experimental period. 
Electrocardiogram measurement 
Twenty four hours (24h) after the last administration of the drugs, the animals were 
anesthetized by intraperitoneal injection of urethane (15 mg/kg). Needle electrodes were 
inserted under the skin of the animals in lead II position. Electrocardiograh recordings were 
made using Biopac Student Lab Experiment system (BSL 3.7, USA). 
Blood collection and assessment of cardiac hypertrophy 
After recording the ECG, blood was collected from the abdominal aorta and allowed to clot 
for 1 h at room temperature. It serum was subsequently separated by centrifugation at 3000g 
for 15 min at 4°C and stored at -20°C for biochemical assays. After the blood collection, the 
animals were euthanized. Their hearts were removed, rinsed in ice-cold normal saline and 
weighed. The wet heart weight to body weight ratio was calculated to assess the degree of 
myocardial weight gain. 
Assay of cardiac marker enzymes 
Activities of lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) in the serum were measured using commercial kits (from Hospitex 
Diagnostics for LDH and FortressDiagnostics for AST and ALT). 
Estimation of lipid peroxidation product and reduced gluthathione in myocardium 
After weighing, the heart tissue was divided into twotransversal parts. One part was 
homogenized in Mc Even physiological ice-cold solution (pH 7.4, 1:5 w/v). The homogenate 
was centrifuged at 3000g for 30 min at 4°C and the supernatant was stored at -20°C for 
biochemical assays.Malondialdehyde (MDA), a thiobarbiturate reactive substance, was 
measured as a marker for oxidative stress in myocardial homogenates using trichloroacetic 
acid (TCA, 20%) and thiobarbituric acid (TBA, 0.67%)
25
. The level of reduced glutathione 
(GSH) was estimated as previously described
26
.  
Histopathological examination 
After weighing, the second part of the heart was fixed in 10% buffered formalin. The fixed 
tissues were embedded in paraffin, sectioned at 5 mm and stained with hematoxylin and eosin 
(H&E). The sections were examined under a light microscope (Scientico STM-50) and 
photomicrographs were taken by a photomicroscope (Minisee 1.0) at x200 magnification. 
Statistical analysis 
Results are shown as mean ± SEM. The statistical comparisons among the groups were 
performed with t-students test using SigmaStat3.5 statistical package program.Mann Whitney 
post-test was employed to compare the mean values between the treated groups and the 
control. P-values less than 0.05 were considered as statistically significant. 
RESULTS 
Effect of Harungana madagascariensis on electrocardiogram 
The Lead II electrocardiograms obtained from the animals are shown in Figure 1. The rats 
receiving distilled water(control group) showed normal patterns of ECG, while those treated 
with isoproterenol alone (ISO group) demonstrated significant changes in ECG pattern. The 
changesincluded a marked elevation of ST segment from 0.11 ± 0.01 mv in control group to 
0.18 ± 0.01 mv in ISO-treated group (P < 0.01) and a reduction in R wave amplitude from 
0.63 ± 0.03 mv in control group to 0.37 ± 0.02 mv in ISO-treated group (P < 0.01) which 
both are indicative of myocardial infarction (Figure 2). Oral treatment with H. 
madagascarienis at a dose of 200 mg/kg or vitamin C (100 mg/kg) resulted in a significant 
 increase in theR-amplitudefrom 0.37 ± 0.02 mv in ISO-treated group to 0.52 ± 0.01 and 0.51 
± 0.02 mv in extract-treated group and vitamin C, respectively (P < 0.01), Figure 
2A).However, treatment with all doses of H. madagascarienis resulted in a non-significant 
decrease in the ST-elevation as compared to the rats treated with isoproterenol alone (Figure 
2B). 
Effects of Harungana madagascariensis on the heart weight to body weight ratio and 
body weight 
The mean body weight of the rats at the end of the experiment in all experimental groups had 
no significant change (Table 1). The heart weight and the ratio of heart weight to the body 
weight were increased significantly (P < 0.05 and P < 0.001 respectively) in ISO-
administered groups when compared with control group. The extract of H. madagascariensis 
when given alone, significantly reduce the heart weight and the ratio of heart weight to body 
weight (P < 0.001) as compared to the ISO-treated group.  
Effect of Harungana madagascariensis on serum marker enzymes 
As shown in Table 2, there was a significant rise observed in the levels of diagnostic marker 
enzymes (LDH (P < 0.01), AST (P < 0.05) and ALT (P < 0.05)) in the serum of the ISO-
treated rats. Pre-treatment with H. madagascariensis(200 and 400 mg/kg) as well as vitamin 
C (100 mg/kg) showed a significant reduction in the levels of all serum diagnostic marker 
enzymes compared to ISO group. 
Effect of Harungana madagascariensis on lipid peroxidation and reduced glutathione 
level 
To determine the lipid peroxidation, MDA levels were measured in myocardial homogenates. 
Heart MDA levels increased insignificantly in isoproterenol alone treated rats as compared to 
the control group (Table 3). Pre-treatment with the H. madagascariensis (200 and 400 
mg/kg) extract induced a dose-dependent but non-significant decrease of MDA levels of 
myocardium.There was a significant (P < 0.001) decrease in GSH level and CAT activity in 
the heart of ISO-treated rats as compared to the control group. Pre-treatment with H. 
madagascariensis (200 and 400 mg/kg) significantly increased(P < 0.001) the myocardial 
GSH level. 
Histopathological examination of the cardiac tissue 
In the control group, myocardial fibers were arranged regularly with clear striation, without 
any damage (Figure 3A). Histopathological sections of the isoproterenol alone treated hearts 
displayed hypertrophy, degeneration of myocytes, infiltration of neutrophilic granulocytes 
and increased edematous inter-muscular space and myofibroblasts (Figure 3B), whereas, the 
rats treated with H. madagascariensisextract (200 and 400 mg/kg) showed protection from 
myocardial injury evidenced by decreased myocytes degeneration as well as edema and 
minimal inflammation (Figure 3C, D). 
DISCUSSION 
The purpose of this work was to evaluate the potential cardioprotective role of Harungana 
madagascariensis aqueous extract stem bark aqueous extract in isoproterenol-induced 
myocardial damage model in rats. ISO in highdoses, induces morphological and functional 
alterations in the heart which closely resembles local myocardial infarction-like pathological 
changes seen in human myocardial infarction
27
. It has been reported that auto-oxidation of 
excess catecholamines such as isoproterenol results in free radical mediated peroxidation of 
membrane phospholipids and consequently leading to permeability changes in the myocardial 
membrane, intracellular calcium overload and irreversible damages
28
. 
Electrocardiogram (ECG) is considered the most important clinical tool for the diagnosis of 
myocardial infarction
29
. In the present study, subcutaneous injection of isoproterenol (85 
mg/kg) for two consecutive days caused ST- segment elevation and R-amplitude depression. 
The elevated ST-segment reflects the potential difference in the boundary between ischemic 
 and non-ischemic zones and a consequent loss of cell membrane function and the depressed 
R-amplitude might be due to the isoproterenol-induced myocardial edema
30
. Harungana 
madagascariensis (200 mg/kg) pre-treatment as well as vitamin C markedly inhibited 
isoproterenol-induced R-amplitude depression and amended the ST-segment elevation, 
indicating its protective effects on cell membrane function and electrical discharges. 
In the present study, we have observed a significant increase in the heart weight and the ratio 
of heart weight to body weight in ISO-treated rats. The observed increase in the heart weight 
in ISO-induced rats might be due to the increased water content, edematous intramuscular 
space and extensive necrosis of cardiac muscle fibers followed by the invasion of damaged 
tissues by the inflammatory cells
30,31
.  
Pre-treatment with the plant extract or vitamin E did not modify this increase. These results 
suggest that AEHM does not affect the gain or loss of weight of this organ. However, the 
short duration of the preventive treatment (seven days) could be responsible for the observed 
result. It would be wise to consider a longer duration in future experiments to better elucidate 
the effects of the plant extract on this parameter. 
Myocardium contains many diagnostic marker enzymes like creatinine kinase, lactate 
dehydrogenase (LDH), aspartate aminotransferase (AST) and alanine aminotrnasferase 
(ALT). Upon administration of isoproterenol, the oxygen demand of the heart increases with 
increase in ionotropic effect in the heart, resulting in prolonged ischemia and glucose 
deprivation. The cells are damaged with increased muscle contractility, which results in 
increasing the cell membranes permeability allowing cardiac enzymes to leak out into the 
bloodstream
32
. Increased activities of these marker enzymes in the serum are indicative of 
cellular damage and loss of functional integrity
33
. In the present study, the significant 
increase observed in the activities of LDH, AST, ALT in the serum of ISO-induced rats may 
be due to the leakage of them from the heart as a result of necrosis induced by ISO.The 
aqueous extract of Harungana madagascariensis seems to preserve the structural and 
functional integrity and/or permeability of the cardiac membrane and thus restricting the 
leakage of these indicative enzymes from the myocardium, as evident from the markedly 
blunted levels of these enzymes in the extracts pre-treated group when compared to the ISO-
treatment group, thereby establishing the cardioprotective effect of the aqueous extract of 
Harungana madagascariensis. 
Malondialdehyde (MDA), a product of the oxidative degradationof unsaturated fatty acids, is 
a biomarker of oxidative stress. Since the major constituents of biological membranes are 
lipids, their peroxidation can lead to cell damage and death
34
.The concentration of MDA 
increases in response tothe free radical production in myocardial infarction, anddecreases by 
antioxidant systems
34
. Increased formation of MDA of 49% as compared to the control group 
is an indication of the severity of the cellular injury to the heart induced by ISO, and this can 
be linked with altered membrane structure and enzyme inactivation
35
.H. madagascariensis 
administration substantiallyreduced MDA levels in a dose-dependent manner by 35 and 42% 
respectively at 200 and 400 mg/kg. 
Glutathione (GSH) is a tripeptide which has a direct antioxidant function by reacting with 
superoxide radicals, peroxy radicals and singletoxygen followed by the formation of oxidized 
GSH and other disulfides. It plays an important role in the regulation of variety of cell 
functions and in cell protection against free radical mediated injury
36, 37
. Depressed GSH 
levels may be associated with an enhanced protective mechanism to oxidative stress in 
myocardial infarction. In this study, ISO administration was found to reduce the levels of 
GSH. This observation concurs with several earlier findings
28, 31, 34
. Decreased GSH levels 
might be due to increased utilization inprotecting ‘SH’ containing proteins from lipid 
peroxides.Pre-treatment with H. madagascariensis(400 mg/kg) significantly improved the 
level of GSH. This points to the potential antioxidant and free radical scavenging activity of 
 H. madagascariensis. Inprevious studies, H. madagascariensis has been described as an 
antioxidant and free radicalscavenger
38,39
. The current studyshowed the antioxidant activity 
of H. madagascariensis and endorses its cardioprotective effect mediated byits antioxidant 
effect in myocardium. 
Histopathological examination of myocardial tissue in the control rats illustrated clear 
integrity of the myocardial cell when compared to the hearts of ISO treated rats. ISO-induced 
rats showedseparations of cardiac muscle fibers, edema and extensive infiltration 
ofneutrophil granulocytes. Pre-treatment with the aqueous extract of H. madagascarienis(200 
and 400 mg/kg) considerably attenuated the edema, reduced inflammatory cell infiltration 
and preserved normal cardiac muscle fibersstructure, further confirming the cardioprotective 
effect of H. madagascarienis. 
CONCLUSION 
In conclusion, our study reveals that pre-treatment of rats with the aqueous extract of H. 
madagascarienis exerts a remarkable protective potential against damages caused by 
isoproterenol-induced myocardial infarction. This cardioprotective effect could be associated 
with the enhancement of antioxidant defense, reduction of lipid peroxydation and is 
confirmed by amending electrocardiographic pattern, improvement of cardiac markers and 
less histopathological damage following isoproterenol-induced myocardial infarction. 
Although this study has provided a possible new therapeutic tool for myocardial infarction, 
more studies are required to elucidate the precise mechanism of H. madagascariensis in 
reversing the pathogenesis of myocardial infarction. 
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TABLES 
Table 1 : Effect of Harungana madagascariensis aqueous extract on heart weight, body 
weight and heart weight/body weight ratio in rats 
Groups Body weight (g) at the end 
of the experimental period 
Heart weight (g) Heart weight/body 
weight ratio (%) 
Control 193.57 ± 8.69 0.61 ± 0.03 0.31 ± 0.01 
ISO 185.01 ± 7.88 0.74 ± 0.03
*
 0.40 ± 0.01
***
 
HM 200+ISO 178.71 ± 4.20 0.71 ± 0.02
*
 0.39 ± 0.01
***
 
HM 400+ISO 179.57 ± 2.42 0.73 ± 0.02
*
 0.40 ± 0.01
***
 
Vit E+ISO 185.00 ± 8.82 0.75 ± 0.03
*
 0.40 ± 0.01
***
 
HM 400 190.29 ± 6.75 0.56 ± 0.02
###
 0.30 ± 0.01
###
 
Vit E 192.86 ± 4.47 0.60 ± 0.04
#
 0.31 ± 0.01
###
 
Values are given as mean ± SEM (n = 7). 
*
P<0.05 and 
***
P < 0.001 as compared to the 
control group; 
#
P<0.05 and 
###
P < 0.001 as compared to the isoprenaline (ISO)-treated group. 
HM 200 or HM 400:Harungana madagascariensis aqueous extract (200 or 400 mg/kg); 
Vit E: vitamin E (100 mg/kg).
 
Table 2 : Effect of Harungana madagascariensis aqueous extract on serum marker 
enzymes 
Groups AST (IU/L)  ALT (IU/L) LDH (IU/L) 
Control 88.44 ± 5.77 32.37 ± 3.68 556.50 ± 50.31 
ISO 109.13 ± 2.55
*
 49.70 ± 4.40
*
 831.42 ± 55.94
**
 
HM 200+ISO 64.79 ± 5.17
##**
 32.05 ± 2.35
##
 208.29 ± 40.92
##**
 
HM 400+ISO 68.88 ± 3.26
##*
 31.30 ± 2.40
##
 370.61 ± 22.82
##*
 
Vit E+ISO 72.96 ± 3.96
##
 31.73 ± 2.87
##
 373.39 ± 49.90
#*
 
HM 400 89.24 ± 2.65  29.10 ± 3.20 418.56 ± 49.01 
Vit E 90.42 ± 3.13 29.24 ± 3.90 569.06 ± 61.39 
Values are given as mean ± SEM (n = 7).
 *
P<0.05 and 
**
P < 0.01 as compared to the control 
group ; 
#
P<0.05 and 
##
P < 0.01 as compared to the isoprenaline (ISO)-treated group. HM 200 
 or HM 400 : Harungana madagascariensis aqueous extract (200 or 400 mg/kg) ; Vit E: 
vitamin E (100 mg/kg). 
Table 3 : The effects of Harungana madagascarienis treatmenton reduced glutathione 
(GSH) and malondialdehyde (MDA) levels in the heart tissue of rats. 
Groups GSH (µmol/g tissue) MDA (µmol/g tissue) 
Control 0.17 ± 0.01  0.42 ± 0.08 
ISO 0.10 ± 0.01
***
 0.85 ± 0.16 
HM 200+ISO 0.14  ± 0.01
##
 0.62 ± 0.07 
HM 400+ISO 0.21 ± 0.01
###**
 0.43 ± 0.06 
Vit E+ISO 0.15  ± 0.01
##
 0.50 ± 0.07 
HM 400 0.19 ±0.01
###
 0.54 ± 0.06 
Vit E 0.18 ± 0.01
###
 0.47 ± 0.04 
Values are given as mean ± SEM (n = 7). **P<0.01 and ***P < 0.001 as compared to the control group ; ##P<0.01 and ###P < 0.001 as 
compared to the isoprenaline (ISO)-treated group. HM 200 or HM 400 : Harungana madagascariensis aqueous extract (200 or 400 mg/kg) ; 
Vit E: vitamin E (100 mg/kg) 
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Figure 1: Representative electrocardiogram tracings of control and experimental 
animals receiving isoproterenol (ISO), Harungana madagascariensis aqueous extract 
(200 or 400 mg/kg) + isoproterenol (HM 200 + ISO or HM 400 + ISO), Vitamin E + 
isoproterenol (Vit E + ISO), the extract alone at 400 mg/kg (HM 400) and vitamin E 
alone (Vit E). The ECG was recorded from II limb leads with recorder speed 0.5 s/div. 
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 Figure 2 : Effects of oral administration of Harungana madagascarienis on R-amplitude 
(A) and ST segment (B) (recorded from limb lead II). Data are reported as mean ± SEM (n = 7). *P<0.05 
and **P < 0.01 as compared to the control group ; ##P < 0.01 as compared to the isoprenaline (ISO)-treated group. HM 200 or HM 400 : 
Harungana madagascariensis aqueous extract (200 or 400 mg/kg) ; Vit : vitamin E (100 mg/kg). 
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Figure 3. Effect of Harungana madagascariensis stem bark aqueous extract (HM) on 
histopathological changes in heart tissue. (A) : normal group received saline showing 
normal structure of myocardium; (B) : diseased group received two subcutaneous injections 
of ISO (85 mg/kg) showing necrosis of myofibrils and edema through penetration of 
inflammatory cells; (C, D) : HM 100 mg/kg and 200 mg/kg treated group showing lesser 
myocardial necrosis and edema following ISO administration. Heart tissues were stained with 
hematoxylin and eosin and visualized under light microscope at x 200 magnification. 
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